The urokinase plasminogen activator system as a target for prognostic studies in breast cancer

13

Transcript of The urokinase plasminogen activator system as a target for prognostic studies in breast cancer

Page 1: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 2: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 3: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 4: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 5: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 6: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 7: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 8: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 9: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 10: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 11: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 12: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 13: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer

Use of intravenous tissue plasminogen activator ... - CDC stacks

Use of intravenous tissue plasminogen activator ... - CDC stacks

Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients

Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients

Tumor Development Is Retarded in Mice Lacking the Gene for Urokinase-Type Plasminogen Activator or Its Inhibitor, Plasminogen Activator Inhibitor1 1

Tumor Development Is Retarded in Mice Lacking the Gene for Urokinase-Type Plasminogen Activator or Its Inhibitor, Plasminogen Activator Inhibitor1 1

Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis

Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis

Vitamins C and E attenuate plasminogen activator inhibitor-1 (PAI-1) expression in a hypercholesterolemic porcine model of angioplasty

Vitamins C and E attenuate plasminogen activator inhibitor-1 (PAI-1) expression in a hypercholesterolemic porcine model of angioplasty

Urokinase versus VATS for treatment of empyema: a randomized multicenter clinical trial

Urokinase versus VATS for treatment of empyema: a randomized multicenter clinical trial

eIF2B activator prevents neurological defects caused by a ...

eIF2B activator prevents neurological defects caused by a ...

Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones

Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones

ORIGINAL ARTICLES Role of Tissue-Type Plasminogen Activator in Salicylic Acid–Induced Sloughing of Human Corn Tissue

ORIGINAL ARTICLES Role of Tissue-Type Plasminogen Activator in Salicylic Acid–Induced Sloughing of Human Corn Tissue

TISSUE INHIBITOR OF METALLOPROTEINASE 1, MATRIX METALLOPROTEINASE 9, ALPHA1 ANTITRYPSIN, METALLOTHIONEIN AND UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR IN SKIN BIOPSIES FROM PATIENTS

TISSUE INHIBITOR OF METALLOPROTEINASE 1, MATRIX METALLOPROTEINASE 9, ALPHA1 ANTITRYPSIN, METALLOTHIONEIN AND UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR IN SKIN BIOPSIES FROM PATIENTS

Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies

Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies

Prevalence of the fibrinogen β-chain, angiotensin-converting enzyme and plasminogen activator inhibitor-1 polymorphisms in Costa Rican young adults with thrombotic disease

Prevalence of the fibrinogen β-chain, angiotensin-converting enzyme and plasminogen activator inhibitor-1 polymorphisms in Costa Rican young adults with thrombotic disease

Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients

Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients

Liver Cirrhosis Is Reverted by Urokinase-Type Plasminogen Activator Gene Therapy

Liver Cirrhosis Is Reverted by Urokinase-Type Plasminogen Activator Gene Therapy

Soluble Urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis

Soluble Urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis

Plasminogen activators in human corneal fibroblasts: secretion, cellular localization, and regulation

Plasminogen activators in human corneal fibroblasts: secretion, cellular localization, and regulation

Urokinase-type Plasminogen Activator-like Proteases in Teleosts Lack Genuine Receptor-binding Epidermal Growth Factor-like Domains

Urokinase-type Plasminogen Activator-like Proteases in Teleosts Lack Genuine Receptor-binding Epidermal Growth Factor-like Domains

Structural and functional characterization of the inhibition of urokinase by. alpha. 2-macroglobulin

Structural and functional characterization of the inhibition of urokinase by. alpha. 2-macroglobulin

PEG-urokinase nanogels with enhanced stability and controllable bioactivity

PEG-urokinase nanogels with enhanced stability and controllable bioactivity

Meta-analysis of the plasminogen activator inhibitor-1 (PAI-1) gene with insertion/deletion 4G/5G polymorphism and its susceptibility to ischemic stroke in Thai population

Meta-analysis of the plasminogen activator inhibitor-1 (PAI-1) gene with insertion/deletion 4G/5G polymorphism and its susceptibility to ischemic stroke in Thai population